钠-葡萄糖共转运蛋白2抑制剂治疗心力衰竭循证证据与机制的研究进展

Research progress in evidence-based evidence and mechanisms of sodium-glucose cotransporter 2 inhibitors in treatment of heart failure

心力衰竭的药物治疗近年取得重大进展。钠-葡萄糖共转运蛋白2(SGLT2)抑制剂是一类不依赖于胰岛素的新型降糖药,能显著降低2型糖尿病患者的血糖和糖化血红蛋白水平。近年发表的DAPA-HF和EMPEROR-Reduced研究显示,SGLT2抑制剂显著改善射血分数降低心力衰竭患者预后,无论患者是否合并糖尿病。上述研究使得心力衰竭基础药物治疗的“黄金三角”转变为“新四联”,心力衰竭药物治疗理念得到革新。

In recent years,great advances have been made in the drug treatment of heart failure.Sodium-glucose cotransporter 2(SGLT2)inhibitors,a new class of insulin-independent hypoglycemic agents,can significantly reduce blood glucose and glycated hemoglobin levels in patients with type 2 diabetes.DAPA-HF and EMPEROR-Reduced studies published in recent years show that SGLT2 inhibitors significantly improve the prognoses of patients suffering from heart failure with reduced ejection fraction(HFrEF),regardless of the presence or absence of type 2 diabetes,eventually transforming the“Golden Triangle”foundational drug treatment of heart failure into the“fantastic four”,and making the drug-treatment idea of heart failure get innovation.